APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Drug Safety and Pharmacovigilance Service

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Drug Safety and Pharmacovigilance Service Market Analysis and Forecast 2026-2032

Report ID 174123190217 January 2026194 pages

Choose your research edition.

Industry ResearchDrug Safety and Pharmacovigilance Service Industry Research Report 2026119 pages · $2,950 USDIndustry Growth & TrendsGlobal Drug Safety and Pharmacovigilance Service Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Drug Safety and Pharmacovigilance Service Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Drug Safety and Pharmacovigilance Service Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Drug Safety and Pharmacovigilance Service Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Drug Safety and Pharmacovigilance Service market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Drug Safety and Pharmacovigilance Service is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Drug Safety and Pharmacovigilance Service is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Drug Safety and Pharmacovigilance Service is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Drug Safety and Pharmacovigilance Service is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Drug Safety and Pharmacovigilance Service include BioPoint, Cmed, Drug Safety Solutions, Hilbrans, Orbis Clinical, Parexel, PharmaLex, ProPharma and SGS, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Drug Safety and Pharmacovigilance Service, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Drug Safety and Pharmacovigilance Service, also provides the revenue of main regions and countries. Of the upcoming market potential for Drug Safety and Pharmacovigilance Service, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Drug Safety and Pharmacovigilance Service revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Drug Safety and Pharmacovigilance Service market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Drug Safety and Pharmacovigilance Service revenue, projected growth trends, production technology, application and end-user industry.

Drug Safety and Pharmacovigilance Service Segment by Company

BioPoint

Cmed

Drug Safety Solutions

Hilbrans

Orbis Clinical

Parexel

PharmaLex

ProPharma

SGS

SJ Pharma Consulting LLC

Vitrana

X7 Research

Drug Safety and Pharmacovigilance Service Segment by Type

Drug Safety Service

Drug Pharmacovigilance Service

Drug Safety and Pharmacovigilance Service Segment by Application

Experimental Stage

Clinical Stage

Postmarketing Stage

Other

Drug Safety and Pharmacovigilance Service Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Drug Safety and Pharmacovigilance Service market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Drug Safety and Pharmacovigilance Service and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Drug Safety and Pharmacovigilance Service.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Drug Safety and Pharmacovigilance Service in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Drug Safety and Pharmacovigilance Service company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Drug Safety and Pharmacovigilance Service revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Drug Safety and Pharmacovigilance Service Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Drug Safety Service Major Player Table 3. Drug Pharmacovigilance Service Major Player Table 4. Global Drug Safety and Pharmacovigilance Service Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Experimental Stage Major Player Table 6. Clinical Stage Major Player Table 7. Postmarketing Stage Major Player Table 8. Other Major Player Table 9. Drug Safety and Pharmacovigilance Service Industry Trends Table 10. Drug Safety and Pharmacovigilance Service Industry Drivers Table 11. Drug Safety and Pharmacovigilance Service Industry Opportunities and Challenges Table 12. Drug Safety and Pharmacovigilance Service Industry Restraints Table 13. Global Drug Safety and Pharmacovigilance Service Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Drug Safety and Pharmacovigilance Service Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Drug Safety and Pharmacovigilance Service Market Share by Region (2021-2026) Table 16. Global Drug Safety and Pharmacovigilance Service Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Drug Safety and Pharmacovigilance Service Market Share by Region (2027-2032) Table 18. Global Drug Safety and Pharmacovigilance Service Revenue by Players (US$ Million) & (2021-2026) Table 19. Global Drug Safety and Pharmacovigilance Service Revenue Market Share by Players (2021-2026) Table 20. Global Drug Safety and Pharmacovigilance Service Key Players Ranking, 2024 VS 2025 VS 2026 Table 21. Global Drug Safety and Pharmacovigilance Service Key Players Headquarters & Area Served Table 22. Global Drug Safety and Pharmacovigilance Service Players, Product Type & Application Table 23. Global Drug Safety and Pharmacovigilance Service Players Establishment Date Table 24. Global Players Market Concentration Ratio (CR5 and HHI) Table 25. Global Drug Safety and Pharmacovigilance Service by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 26. Global Drug Safety and Pharmacovigilance Service Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Drug Safety and Pharmacovigilance Service Revenue by Type (2021-2026) & (US$ Million) Table 28. Global Drug Safety and Pharmacovigilance Service Revenue by Type (2027-2032) & (US$ Million) Table 29. Global Drug Safety and Pharmacovigilance Service Revenue Market Share by Type (2021-2026) Table 30. Global Drug Safety and Pharmacovigilance Service Revenue Market Share by Type (2027-2032) Table 31. Global Drug Safety and Pharmacovigilance Service Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Drug Safety and Pharmacovigilance Service Revenue by Application (2021-2026) & (US$ Million) Table 33. Global Drug Safety and Pharmacovigilance Service Revenue by Application (2027-2032) & (US$ Million) Table 34. Global Drug Safety and Pharmacovigilance Service Revenue Market Share by Application (2021-2026) Table 35. Global Drug Safety and Pharmacovigilance Service Revenue Market Share by Application (2027-2032) Table 36. BioPoint Company Information Table 37. BioPoint Business Overview Table 38. BioPoint Drug Safety and Pharmacovigilance Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. BioPoint Drug Safety and Pharmacovigilance Service Product Portfolio Table 40. BioPoint Recent Development Table 41. Cmed Company Information Table 42. Cmed Business Overview Table 43. Cmed Drug Safety and Pharmacovigilance Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. Cmed Drug Safety and Pharmacovigilance Service Product Portfolio Table 45. Cmed Recent Development Table 46. Drug Safety Solutions Company Information Table 47. Drug Safety Solutions Business Overview Table 48. Drug Safety Solutions Drug Safety and Pharmacovigilance Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. Drug Safety Solutions Drug Safety and Pharmacovigilance Service Product Portfolio Table 50. Drug Safety Solutions Recent Development Table 51. Hilbrans Company Information Table 52. Hilbrans Business Overview Table 53. Hilbrans Drug Safety and Pharmacovigilance Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. Hilbrans Drug Safety and Pharmacovigilance Service Product Portfolio Table 55. Hilbrans Recent Development Table 56. Orbis Clinical Company Information Table 57. Orbis Clinical Business Overview Table 58. Orbis Clinical Drug Safety and Pharmacovigilance Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. Orbis Clinical Drug Safety and Pharmacovigilance Service Product Portfolio Table 60. Orbis Clinical Recent Development Table 61. Parexel Company Information Table 62. Parexel Business Overview Table 63. Parexel Drug Safety and Pharmacovigilance Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. Parexel Drug Safety and Pharmacovigilance Service Product Portfolio Table 65. Parexel Recent Development Table 66. PharmaLex Company Information Table 67. PharmaLex Business Overview Table 68. PharmaLex Drug Safety and Pharmacovigilance Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. PharmaLex Drug Safety and Pharmacovigilance Service Product Portfolio Table 70. PharmaLex Recent Development Table 71. ProPharma Company Information Table 72. ProPharma Business Overview Table 73. ProPharma Drug Safety and Pharmacovigilance Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. ProPharma Drug Safety and Pharmacovigilance Service Product Portfolio Table 75. ProPharma Recent Development Table 76. SGS Company Information Table 77. SGS Business Overview Table 78. SGS Drug Safety and Pharmacovigilance Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 79. SGS Drug Safety and Pharmacovigilance Service Product Portfolio Table 80. SGS Recent Development Table 81. SJ Pharma Consulting LLC Company Information Table 82. SJ Pharma Consulting LLC Business Overview Table 83. SJ Pharma Consulting LLC Drug Safety and Pharmacovigilance Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 84. SJ Pharma Consulting LLC Drug Safety and Pharmacovigilance Service Product Portfolio Table 85. SJ Pharma Consulting LLC Recent Development Table 86. Vitrana Company Information Table 87. Vitrana Business Overview Table 88. Vitrana Drug Safety and Pharmacovigilance Service Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 89. Vitrana Drug Safety and Pharmacovigilance Service Product Portfolio Table 90. Vitrana Recent Development Table 91. X7 Research Company Information Table 92. X7 Research Business Overview Table 93. X7 Research Drug Safety and Pharmacovigilance Service Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 94. X7 Research Drug Safety and Pharmacovigilance Service Product Portfolio Table 95. X7 Research Recent Development Table 96. North America Drug Safety and Pharmacovigilance Service Revenue by Type (2021-2026) & (US$ Million) Table 97. North America Drug Safety and Pharmacovigilance Service Revenue by Type (2027-2032) & (US$ Million) Table 98. North America Drug Safety and Pharmacovigilance Service Revenue by Application (2021-2026) & (US$ Million) Table 99. North America Drug Safety and Pharmacovigilance Service Revenue by Application (2027-2032) & (US$ Million) Table 100. North America Drug Safety and Pharmacovigilance Service Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 101. North America Drug Safety and Pharmacovigilance Service Revenue by Country (2021-2026) & (US$ Million) Table 102. North America Drug Safety and Pharmacovigilance Service Revenue by Country (US$ Million) & (2027-2032) Table 103. Europe Drug Safety and Pharmacovigilance Service Revenue by Type (2021-2026) & (US$ Million) Table 104. Europe Drug Safety and Pharmacovigilance Service Revenue by Type (2027-2032) & (US$ Million) Table 105. Europe Drug Safety and Pharmacovigilance Service Revenue by Application (2021-2026) & (US$ Million) Table 106. Europe Drug Safety and Pharmacovigilance Service Revenue by Application (2027-2032) & (US$ Million) Table 107. Europe Drug Safety and Pharmacovigilance Service Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 108. Europe Drug Safety and Pharmacovigilance Service Revenue by Country (2021-2026) & (US$ Million) Table 109. Europe Drug Safety and Pharmacovigilance Service Revenue by Country (US$ Million) & (2027-2032) Table 110. China Drug Safety and Pharmacovigilance Service Revenue by Type (2021-2026) & (US$ Million) Table 111. China Drug Safety and Pharmacovigilance Service Revenue by Type (2027-2032) & (US$ Million) Table 112. China Drug Safety and Pharmacovigilance Service Revenue by Application (2021-2026) & (US$ Million) Table 113. China Drug Safety and Pharmacovigilance Service Revenue by Application (2027-2032) & (US$ Million) Table 114. Asia Drug Safety and Pharmacovigilance Service Revenue by Type (2021-2026) & (US$ Million) Table 115. Asia Drug Safety and Pharmacovigilance Service Revenue by Type (2027-2032) & (US$ Million) Table 116. Asia Drug Safety and Pharmacovigilance Service Revenue by Application (2021-2026) & (US$ Million) Table 117. Asia Drug Safety and Pharmacovigilance Service Revenue by Application (2027-2032) & (US$ Million) Table 118. Asia Drug Safety and Pharmacovigilance Service Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 119. Asia Drug Safety and Pharmacovigilance Service Revenue by Region (US$ Million) & (2021-2026) Table 120. Asia Drug Safety and Pharmacovigilance Service Revenue by Region (US$ Million) & (2027-2032) Table 121. SAMEA Drug Safety and Pharmacovigilance Service Revenue by Type (2021-2026) & (US$ Million) Table 122. SAMEA Drug Safety and Pharmacovigilance Service Revenue by Type (2027-2032) & (US$ Million) Table 123. SAMEA Drug Safety and Pharmacovigilance Service Revenue by Application (2021-2026) & (US$ Million) Table 124. SAMEA Drug Safety and Pharmacovigilance Service Revenue by Application (2027-2032) & (US$ Million) Table 125. SAMEA Drug Safety and Pharmacovigilance Service Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 126. SAMEA Drug Safety and Pharmacovigilance Service Revenue by Country (2021-2026) & (US$ Million) Table 127. SAMEA Drug Safety and Pharmacovigilance Service Revenue by Country (US$ Million) & (2027-2032) Table 128. Research Programs/Design for This Report Table 129. Authors List of This Report Table 130. Secondary Sources Table 131. Primary Sources List of Figures Figure 1. Drug Safety and Pharmacovigilance Service Image Figure 2. Global Drug Safety and Pharmacovigilance Service Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Drug Safety and Pharmacovigilance Service Market Size Share 2021 VS 2025 VS 2032 Figure 4. Drug Safety Service Image Figure 5. Drug Pharmacovigilance Service Image Figure 6. Global Drug Safety and Pharmacovigilance Service Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Drug Safety and Pharmacovigilance Service Market Size Share 2021 VS 2025 VS 2032 Figure 8. Experimental Stage Image Figure 9. Clinical Stage Image Figure 10. Postmarketing Stage Image Figure 11. Other Image Figure 12. Global Drug Safety and Pharmacovigilance Service Market Size (US$ Million) & (2021-2032) Figure 13. Global Drug Safety and Pharmacovigilance Service Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Drug Safety and Pharmacovigilance Service Market Share by Region: 2021 VS 2025 VS 2032 Figure 15. Global Drug Safety and Pharmacovigilance Service Players Revenue Share Top 10 and Top 5 in 2025 Figure 16. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global Drug Safety and Pharmacovigilance Service Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Drug Safety and Pharmacovigilance Service Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Drug Safety and Pharmacovigilance Service Revenue Market Share by Type (2021-2032) Figure 20. Global Drug Safety and Pharmacovigilance Service Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Drug Safety and Pharmacovigilance Service Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 22. Global Drug Safety and Pharmacovigilance Service Revenue Market Share by Application (2021-2032) Figure 23. North America Drug Safety and Pharmacovigilance Service Revenue YoY Growth (2021-2032) & (US$ Million) Figure 24. North America Drug Safety and Pharmacovigilance Service Revenue Share by Type (2021-2032) Figure 25. North America Drug Safety and Pharmacovigilance Service Revenue Share by Application (2021-2032) Figure 26. North America Drug Safety and Pharmacovigilance Service Revenue Share by Country (2021-2032) Figure 27. United States Drug Safety and Pharmacovigilance Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Canada Drug Safety and Pharmacovigilance Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Mexico Drug Safety and Pharmacovigilance Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Europe Drug Safety and Pharmacovigilance Service Revenue YoY Growth (2021-2032) & (US$ Million) Figure 31. Europe Drug Safety and Pharmacovigilance Service Revenue Share by Type (2021-2032) Figure 32. Europe Drug Safety and Pharmacovigilance Service Revenue Share by Application (2021-2032) Figure 33. Europe Drug Safety and Pharmacovigilance Service Revenue Share by Country (2021-2032) Figure 34. Germany Drug Safety and Pharmacovigilance Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. France Drug Safety and Pharmacovigilance Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. U.K. Drug Safety and Pharmacovigilance Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Italy Drug Safety and Pharmacovigilance Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Spain Drug Safety and Pharmacovigilance Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Russia Drug Safety and Pharmacovigilance Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Netherlands Drug Safety and Pharmacovigilance Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Nordic Countries Drug Safety and Pharmacovigilance Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. China Drug Safety and Pharmacovigilance Service Revenue YoY Growth (2021-2032) & (US$ Million) Figure 43. China Drug Safety and Pharmacovigilance Service Revenue Share by Type (2021-2032) Figure 44. China Drug Safety and Pharmacovigilance Service Revenue Share by Application (2021-2032) Figure 45. Asia Drug Safety and Pharmacovigilance Service Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. Asia Drug Safety and Pharmacovigilance Service Revenue Share by Type (2021-2032) Figure 47. Asia Drug Safety and Pharmacovigilance Service Revenue Share by Application (2021-2032) Figure 48. Asia Drug Safety and Pharmacovigilance Service Revenue Share by Region (2021-2032) Figure 49. Japan Drug Safety and Pharmacovigilance Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. South Korea Drug Safety and Pharmacovigilance Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. India Drug Safety and Pharmacovigilance Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Australia Drug Safety and Pharmacovigilance Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Taiwan Drug Safety and Pharmacovigilance Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Southeast Asia Drug Safety and Pharmacovigilance Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. SAMEA Drug Safety and Pharmacovigilance Service Revenue YoY Growth (2021-2032) & (US$ Million) Figure 56. SAMEA Drug Safety and Pharmacovigilance Service Revenue Share by Type (2021-2032) Figure 57. SAMEA Drug Safety and Pharmacovigilance Service Revenue Share by Application (2021-2032) Figure 58. SAMEA Drug Safety and Pharmacovigilance Service Revenue Share by Country (2021-2032) Figure 59. Brazil Drug Safety and Pharmacovigilance Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Argentina Drug Safety and Pharmacovigilance Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Chile Drug Safety and Pharmacovigilance Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Colombia Drug Safety and Pharmacovigilance Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Peru Drug Safety and Pharmacovigilance Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Saudi Arabia Drug Safety and Pharmacovigilance Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Israel Drug Safety and Pharmacovigilance Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. UAE Drug Safety and Pharmacovigilance Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Turkey Drug Safety and Pharmacovigilance Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Iran Drug Safety and Pharmacovigilance Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Egypt Drug Safety and Pharmacovigilance Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Drug Safety Service
  • Drug Pharmacovigilance Service
Applications
  • Experimental Stage
  • Clinical Stage
  • Postmarketing Stage
  • Other
Companies covered
  • BioPoint
  • Cmed
  • Drug Safety Solutions
  • Hilbrans
  • Orbis Clinical
  • Parexel
  • PharmaLex
  • ProPharma
  • SGS
  • SJ Pharma Consulting LLC
  • Vitrana
  • X7 Research

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Drug Safety and Pharmacovigilance Service Market by Type
  3. 1.2.1 Global Drug Safety and Pharmacovigilance Service Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Drug Safety Service
  5. 1.2.3 Drug Pharmacovigilance Service
  6. 1.3 Drug Safety and Pharmacovigilance Service Market by Application
  7. 1.3.1 Global Drug Safety and Pharmacovigilance Service Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Experimental Stage
  9. 1.3.3 Clinical Stage
  10. 1.3.4 Postmarketing Stage
  11. 1.3.5 Other
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Drug Safety and Pharmacovigilance Service Market Dynamics
  1. 2.1 Drug Safety and Pharmacovigilance Service Industry Trends
  2. 2.2 Drug Safety and Pharmacovigilance Service Industry Drivers
  3. 2.3 Drug Safety and Pharmacovigilance Service Industry Opportunities and Challenges
  4. 2.4 Drug Safety and Pharmacovigilance Service Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Drug Safety and Pharmacovigilance Service Market Perspective (2021-2032)
  2. 3.2 Global Drug Safety and Pharmacovigilance Service Growth Trends by Region
  3. 3.2.1 Global Drug Safety and Pharmacovigilance Service Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Drug Safety and Pharmacovigilance Service Market Size by Region (2021-2026)
  5. 3.2.3 Global Drug Safety and Pharmacovigilance Service Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Drug Safety and Pharmacovigilance Service Revenue by Players
  2. 4.1.1 Global Drug Safety and Pharmacovigilance Service Revenue by Players (2021-2026)
  3. 4.1.2 Global Drug Safety and Pharmacovigilance Service Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Drug Safety and Pharmacovigilance Service Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Drug Safety and Pharmacovigilance Service Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Drug Safety and Pharmacovigilance Service Key Players Headquarters & Area Served
  7. 4.4 Global Drug Safety and Pharmacovigilance Service Players, Product Type & Application
  8. 4.5 Global Drug Safety and Pharmacovigilance Service Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Drug Safety and Pharmacovigilance Service Market CR5 and HHI
  11. 4.6.3 2025 Drug Safety and Pharmacovigilance Service Tier 1, Tier 2, and Tier 3
5 Drug Safety and Pharmacovigilance Service Market Size by Type
  1. 5.1 Global Drug Safety and Pharmacovigilance Service Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Drug Safety and Pharmacovigilance Service Revenue by Type (2021-2032)
  3. 5.3 Global Drug Safety and Pharmacovigilance Service Revenue Market Share by Type (2021-2032)
6 Drug Safety and Pharmacovigilance Service Market Size by Application
  1. 6.1 Global Drug Safety and Pharmacovigilance Service Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Drug Safety and Pharmacovigilance Service Revenue by Application (2021-2032)
  3. 6.3 Global Drug Safety and Pharmacovigilance Service Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 BioPoint
  2. 7.1.1 BioPoint Company Information
  3. 7.1.2 BioPoint Business Overview
  4. 7.1.3 BioPoint Drug Safety and Pharmacovigilance Service Revenue and Gross Margin (2021-2026)
  5. 7.1.4 BioPoint Drug Safety and Pharmacovigilance Service Product Portfolio
  6. 7.1.5 BioPoint Recent Developments
  7. 7.2 Cmed
  8. 7.2.1 Cmed Company Information
  9. 7.2.2 Cmed Business Overview
  10. 7.2.3 Cmed Drug Safety and Pharmacovigilance Service Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Cmed Drug Safety and Pharmacovigilance Service Product Portfolio
  12. 7.2.5 Cmed Recent Developments
  13. 7.3 Drug Safety Solutions
  14. 7.3.1 Drug Safety Solutions Company Information
  15. 7.3.2 Drug Safety Solutions Business Overview
  16. 7.3.3 Drug Safety Solutions Drug Safety and Pharmacovigilance Service Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Drug Safety Solutions Drug Safety and Pharmacovigilance Service Product Portfolio
  18. 7.3.5 Drug Safety Solutions Recent Developments
  19. 7.4 Hilbrans
  20. 7.4.1 Hilbrans Company Information
  21. 7.4.2 Hilbrans Business Overview
  22. 7.4.3 Hilbrans Drug Safety and Pharmacovigilance Service Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Hilbrans Drug Safety and Pharmacovigilance Service Product Portfolio
  24. 7.4.5 Hilbrans Recent Developments
  25. 7.5 Orbis Clinical
  26. 7.5.1 Orbis Clinical Company Information
  27. 7.5.2 Orbis Clinical Business Overview
  28. 7.5.3 Orbis Clinical Drug Safety and Pharmacovigilance Service Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Orbis Clinical Drug Safety and Pharmacovigilance Service Product Portfolio
  30. 7.5.5 Orbis Clinical Recent Developments
  31. 7.6 Parexel
  32. 7.6.1 Parexel Company Information
  33. 7.6.2 Parexel Business Overview
  34. 7.6.3 Parexel Drug Safety and Pharmacovigilance Service Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Parexel Drug Safety and Pharmacovigilance Service Product Portfolio
  36. 7.6.5 Parexel Recent Developments
  37. 7.7 PharmaLex
  38. 7.7.1 PharmaLex Company Information
  39. 7.7.2 PharmaLex Business Overview
  40. 7.7.3 PharmaLex Drug Safety and Pharmacovigilance Service Revenue and Gross Margin (2021-2026)
  41. 7.7.4 PharmaLex Drug Safety and Pharmacovigilance Service Product Portfolio
  42. 7.7.5 PharmaLex Recent Developments
  43. 7.8 ProPharma
  44. 7.8.1 ProPharma Company Information
  45. 7.8.2 ProPharma Business Overview
  46. 7.8.3 ProPharma Drug Safety and Pharmacovigilance Service Revenue and Gross Margin (2021-2026)
  47. 7.8.4 ProPharma Drug Safety and Pharmacovigilance Service Product Portfolio
  48. 7.8.5 ProPharma Recent Developments
  49. 7.9 SGS
  50. 7.9.1 SGS Company Information
  51. 7.9.2 SGS Business Overview
  52. 7.9.3 SGS Drug Safety and Pharmacovigilance Service Revenue and Gross Margin (2021-2026)
  53. 7.9.4 SGS Drug Safety and Pharmacovigilance Service Product Portfolio
  54. 7.9.5 SGS Recent Developments
  55. 7.10 SJ Pharma Consulting LLC
  56. 7.10.1 SJ Pharma Consulting LLC Company Information
  57. 7.10.2 SJ Pharma Consulting LLC Business Overview
  58. 7.10.3 SJ Pharma Consulting LLC Drug Safety and Pharmacovigilance Service Revenue and Gross Margin (2021-2026)
  59. 7.10.4 SJ Pharma Consulting LLC Drug Safety and Pharmacovigilance Service Product Portfolio
  60. 7.10.5 SJ Pharma Consulting LLC Recent Developments
  61. 7.11 Vitrana
  62. 7.11.1 Vitrana Company Information
  63. 7.11.2 Vitrana Business Overview
  64. 7.11.3 Vitrana Drug Safety and Pharmacovigilance Service Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Vitrana Drug Safety and Pharmacovigilance Service Product Portfolio
  66. 7.11.5 Vitrana Recent Developments
  67. 7.12 X7 Research
  68. 7.12.1 X7 Research Company Information
  69. 7.12.2 X7 Research Business Overview
  70. 7.12.3 X7 Research Drug Safety and Pharmacovigilance Service Revenue and Gross Margin (2021-2026)
  71. 7.12.4 X7 Research Drug Safety and Pharmacovigilance Service Product Portfolio
  72. 7.12.5 X7 Research Recent Developments
8 North America
  1. 8.1 North America Drug Safety and Pharmacovigilance Service Revenue (2021-2032)
  2. 8.2 North America Drug Safety and Pharmacovigilance Service Revenue by Type (2021-2032)
  3. 8.2.1 North America Drug Safety and Pharmacovigilance Service Revenue by Type (2021-2026)
  4. 8.2.2 North America Drug Safety and Pharmacovigilance Service Revenue by Type (2027-2032)
  5. 8.3 North America Drug Safety and Pharmacovigilance Service Revenue Share by Type (2021-2032)
  6. 8.4 North America Drug Safety and Pharmacovigilance Service Revenue by Application (2021-2032)
  7. 8.4.1 North America Drug Safety and Pharmacovigilance Service Revenue by Application (2021-2026)
  8. 8.4.2 North America Drug Safety and Pharmacovigilance Service Revenue by Application (2027-2032)
  9. 8.5 North America Drug Safety and Pharmacovigilance Service Revenue Share by Application (2021-2032)
  10. 8.6 North America Drug Safety and Pharmacovigilance Service Revenue by Country
  11. 8.6.1 North America Drug Safety and Pharmacovigilance Service Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Drug Safety and Pharmacovigilance Service Revenue by Country (2021-2026)
  13. 8.6.3 North America Drug Safety and Pharmacovigilance Service Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Drug Safety and Pharmacovigilance Service Revenue (2021-2032)
  2. 9.2 Europe Drug Safety and Pharmacovigilance Service Revenue by Type (2021-2032)
  3. 9.2.1 Europe Drug Safety and Pharmacovigilance Service Revenue by Type (2021-2026)
  4. 9.2.2 Europe Drug Safety and Pharmacovigilance Service Revenue by Type (2027-2032)
  5. 9.3 Europe Drug Safety and Pharmacovigilance Service Revenue Share by Type (2021-2032)
  6. 9.4 Europe Drug Safety and Pharmacovigilance Service Revenue by Application (2021-2032)
  7. 9.4.1 Europe Drug Safety and Pharmacovigilance Service Revenue by Application (2021-2026)
  8. 9.4.2 Europe Drug Safety and Pharmacovigilance Service Revenue by Application (2027-2032)
  9. 9.5 Europe Drug Safety and Pharmacovigilance Service Revenue Share by Application (2021-2032)
  10. 9.6 Europe Drug Safety and Pharmacovigilance Service Revenue by Country
  11. 9.6.1 Europe Drug Safety and Pharmacovigilance Service Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Drug Safety and Pharmacovigilance Service Revenue by Country (2021-2026)
  13. 9.6.3 Europe Drug Safety and Pharmacovigilance Service Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Drug Safety and Pharmacovigilance Service Revenue (2021-2032)
  2. 10.2 China Drug Safety and Pharmacovigilance Service Revenue by Type (2021-2032)
  3. 10.2.1 China Drug Safety and Pharmacovigilance Service Revenue by Type (2021-2026)
  4. 10.2.2 China Drug Safety and Pharmacovigilance Service Revenue by Type (2027-2032)
  5. 10.3 China Drug Safety and Pharmacovigilance Service Revenue Share by Type (2021-2032)
  6. 10.4 China Drug Safety and Pharmacovigilance Service Revenue by Application (2021-2032)
  7. 10.4.1 China Drug Safety and Pharmacovigilance Service Revenue by Application (2021-2026)
  8. 10.4.2 China Drug Safety and Pharmacovigilance Service Revenue by Application (2027-2032)
  9. 10.5 China Drug Safety and Pharmacovigilance Service Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Drug Safety and Pharmacovigilance Service Revenue (2021-2032)
  2. 11.2 Asia Drug Safety and Pharmacovigilance Service Revenue by Type (2021-2032)
  3. 11.2.1 Asia Drug Safety and Pharmacovigilance Service Revenue by Type (2021-2026)
  4. 11.2.2 Asia Drug Safety and Pharmacovigilance Service Revenue by Type (2027-2032)
  5. 11.3 Asia Drug Safety and Pharmacovigilance Service Revenue Share by Type (2021-2032)
  6. 11.4 Asia Drug Safety and Pharmacovigilance Service Revenue by Application (2021-2032)
  7. 11.4.1 Asia Drug Safety and Pharmacovigilance Service Revenue by Application (2021-2026)
  8. 11.4.2 Asia Drug Safety and Pharmacovigilance Service Revenue by Application (2027-2032)
  9. 11.5 Asia Drug Safety and Pharmacovigilance Service Revenue Share by Application (2021-2032)
  10. 11.6 Asia Drug Safety and Pharmacovigilance Service Revenue by Country
  11. 11.6.1 Asia Drug Safety and Pharmacovigilance Service Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Drug Safety and Pharmacovigilance Service Revenue by Country (2021-2026)
  13. 11.6.3 Asia Drug Safety and Pharmacovigilance Service Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Drug Safety and Pharmacovigilance Service Revenue (2021-2032)
  2. 12.2 SAMEA Drug Safety and Pharmacovigilance Service Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Drug Safety and Pharmacovigilance Service Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Drug Safety and Pharmacovigilance Service Revenue by Type (2027-2032)
  5. 12.3 SAMEA Drug Safety and Pharmacovigilance Service Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Drug Safety and Pharmacovigilance Service Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Drug Safety and Pharmacovigilance Service Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Drug Safety and Pharmacovigilance Service Revenue by Application (2027-2032)
  9. 12.5 SAMEA Drug Safety and Pharmacovigilance Service Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Drug Safety and Pharmacovigilance Service Revenue by Country
  11. 12.6.1 SAMEA Drug Safety and Pharmacovigilance Service Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Drug Safety and Pharmacovigilance Service Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Drug Safety and Pharmacovigilance Service Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst